Cover Image
Market Research Report
Product code 
986220

Cell Line Development and Characterization Services by Sources of Cell Lines / Expression Systems (Mammalian, Microbial, Insect, Avian and Others), Applications of Cell Lines (Research and Development and Drug Development)

Published: | Roots Analysis | 483 Pages | Delivery time: 1-2 business days

Price

Back to Top
Cell Line Development and Characterization Services by Sources of Cell Lines / Expression Systems (Mammalian, Microbial, Insect, Avian and Others), Applications of Cell Lines (Research and Development and Drug Development)
Published: January 31, 2021
Roots Analysis
Content info: 483 Pages
Delivery time: 1-2 business days
  • ALL
  • Description
  • Table of Contents
Description

Title:
Cell Line Development and Characterization Services
by Sources of Cell Lines / Expression Systems (Mammalian, Microbial, Insect, Avian and Others), Applications of Cell Lines (Research and Development and Drug Development), and Geography (North America, Europe, Asia Pacific and Rest of the World): Industry Trends and Global Forecasts (2nd Edition), 2020-2030.

Overview:

Over the years, the biopharmaceutical market has grown into a promising, high value vertical within the overall pharmaceutical industry. In fact, nearly 29% and 25% of the total number of novel drugs approved by the Food and Drug Administration's Center for Drug Evaluation and Research (CDER) in 2018 and 2019, respectively, were biologics. As a result, the pipeline of biologics and biosimilars is growing at a commendable pace. Given that the development and manufacturing of such therapies require living biological systems, there has been a surge in demand for different types of cell lines. In fact, around 84% of the therapeutic proteins marketed in the last five years, were produced using various mammalian and microbial cells. A recent study revealed that over 30,000 research articles published in 33,000 journals featured data generated from experiments that used misidentified or contaminated cell lines. This is a genuine concern in the field of medical research, which is becoming increasingly dependent on cell-based assays and experimentation. Therefore, in modern medical research, proper cell line characterization is a necessity in order to preserve the authenticity and accuracy of experimental research.

Given the cost intensive nature of pharmacological R&D, medical researchers / drug developers are consistently on the lookout for ways to optimize operational efficiencies, as well as reduce affiliated costs; in this context, outsourcing has emerged as a preferred business model. Presently, there are several contact service providers that claim to have the necessary expertise to develop and characterize cell lines. The technical aspect of this field is also witnessing a lot of innovation, especially with regard to automating various steps of the cell line development process. New genome editing technologies, such as the CRISPR/Cas-9, are also being extensively used to improve the quality of recombinant cell lines. Unlike drug developers, the capabilities of service providers are usually more focused to their respective service portfolios. Moreover, such companies ensure that they have the latest upgrades in equipment and infrastructure, in order to improve the quality of services offered. In fact, in the recent past, a number of service providers offering cell lines-related services, have forged strategic alliances with and / or acquired other players, in order to further enhance their respective portfolios. Considering the growing trend of outsourcing and the ongoing efforts of service providers to improve / expand their offerings, we believe the contract services market for cell line development and characterization is likely to evolve at a steady pace, till 2030.

Scope of the Report:

The "Cell Line Development and Characterization Services Market (2nd Edition), 2020-2030" report features an extensive study on the current market landscape, offering an informed opinion on the likely evolution in this industry, over the next ten years. The study underlines an in-depth analysis of the services offered for the development and characterization of cell lines, which are intended for use in various R&D and / or therapeutic purposes. In addition to other elements, it includes:

  • A detailed review of the overall landscape of the cell line development services market, highlighting the contributions of contract service providers, along with the information on year of establishment, company size, location of headquarters, sources of cell lines and expression systems offered (mammalian, microbial, insect and avian), integrated cell line characterization, biosimilar cell line development and gene editing cell line development services offered, gene delivery method used (physical, chemical, biological and non-biological), type of gene expression (stable and transient), usage of serum-free / animal component free cell culture media, types of cell cultures (suspension and mixed growth properties), types of cells offered (recombinant, hybridoma and primary), applications of cell lines (R&D, biomanufacturing, diagnostics and cell therapy / regenerative medicine / tissue culture). In addition, the chapter includes information on additional cell line related services (bio-analytical / protein purification, cell banking, cell bank characterization, process development, GMP manufacturing and fill-finish), types of cell banks developed (master cell banks, working cell banks, research cell banks and end-of-production cell banks) and protein yield from cell lines.
  • A company competitiveness analysis, highlighting prominent cell line development service providers based in different regions, taking into consideration their supplier strength (experience of the service provider), and portfolio specifications (sources of cell lines and expression systems handled, availability of proprietary / licensed technology platform, type of gene expression and availability of additional cell line related services).
  • Elaborate profiles of cell line development service providers. Each company profile features a brief overview of the company, its financial information (if available), cell line development and complementary services portfolio and an informed future outlook.
  • A detailed review of the overall landscape of the cell line characterization services market, highlighting the contributions of industry and non-industry players along with the information on year of establishment, company size, location of headquarters, types of cells handled (mammalian, microbial, insect and others), types of cell line characterization services offered (identity / stability testing, sterility / biosafety testing, expression testing and oncogenicity / tumorigenicity testing), types of cell line identity / stability testing services offered (analysis of cell morphology, cytochrome c oxidase 1 barcoding assay, DNA fingerprinting / profiling, gene copy number analysis, isozyme analysis, karyotype analysis, nucleic acid sequencing, southern blotting and viability testing) types of sterility / biosafety testing services offered (mycoplasma contamination testing, microbial contamination testing, viral / adventitious agents contamination testing, retroviral contamination testing and rodent virus testing / in-vivo biosafety testing), availability of other cell line related services (cell line development, cell banking and mycoplasma clearance service), information on regulatory accreditations / certifications and overall turnaround time. In addition, it lists the non-industry players and provides information on number of STR loci amplified, type of genotyping kit used and service fee charged.
  • A company competitiveness analysis, highlighting prominent cell line characterization service providers based in different regions, taking into consideration their supplier strength (experience of the service provider), and portfolio specifications (sources of cell lines and expression systems handled and size of the service portfolio.)
  • Elaborate profiles of cell line characterization service providers. Each company profile features a brief overview of the company, its financial information (if available), cell line characterization services portfolio and an informed future outlook.
  • A detailed analysis of the partnerships that have been established in the cell line development and characterization domain since 2015, covering technology platform utilization agreements, R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, process development agreements, clinical trial agreements, and other relevant deals.
  • Detailed profiles of the biorepositories across the globe that play an important role in developing cell lines and have also undertaken initiatives to limit the use of contaminated and / or misidentified cell lines. Each profile features a brief overview of the repository and its cell line characterization service portfolio.
  • An elaborate discussion on the requirements established by various regulatory authorities, across different regions, related to characterization of cell lines. In addition, it provides insights from the various guideline documents that have been issued by these bodies on protocols that need to be followed and general tips for the testing of cell lines. It also features a brief historical overview and discussion on the contributions of key institutes / organizations involved in this domain.
  • A survey analysis featuring inputs solicited from various experts who are directly / indirectly involved in providing cell line development and / or cell line characterization services.

One of the key objectives of the report was to estimate the existing market size and future growth opportunities for cell line development and characterization service providers. Based on multiple parameters, such as the number of projects completed annually, price of the projects, the overall R&D expenditure available to CROs and the overall growth of the biologics market, we have developed informed estimates on the financial evolution of the market over the period 2020-2030.

For cell line development services market, our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] sources of cell lines and expression systems (mammalian, microbial, insect and avian), [B] applications of cell lines (R&D operations and drug development), [C] company size (small, mid-sized and large) and key geographies (North America, Europe, Asia, Oceania and Rest of the World).

For cell line characterization services market, our year-wise projections of the current and future opportunity have further been segmented on the basis of [A] sources of cell lines and expression systems (mammalian, microbial and others), [B] applications of cell lines (R&D operations and drug development), [C] type of service provider (industry players and non-industry players) and [D] key geographies (North America, Europe, Asia, Middle East & North Africa (MENA), Latin America (LATAM) and Rest of the World (RoW)).

To account for the uncertainties associated with this industry and to add robustness to our model, we have provided three forecast scenarios, portraying the conservative, base and optimistic tracks of the market's evolution.

The opinions and insights presented in this study were influenced by inputs solicited via a comprehensive survey and discussions conducted with several key players in this domain. The report features detailed transcripts of interviews held with the following industry stakeholders (in reverse chronological order):

  • Fai Poon (Founder and President, Quacell Biotechnology)
  • Louis Boon (Chief Scientific Officer, Polpharma Biologics)
  • Fan Chen (Former Vice President BioProcessing, LakePharma)
  • Michael Pointek (Founder and Managing Director, ARTES Biotechnology)
  • Nienke Smits (Client Relations Manager, Immunoprecise Antibodies)
  • Oscar Hoogteijling (Former Global Business Development Manager, Polpharma Biologics)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered:

  • Who are the leading players offering cell line development services?
  • What kind of CDMO support is available for cell line development, across different regions?
  • What are the common sources, gene delivery methods, protein yield and affiliated services offered by the cell line development service providers?
  • Who are the leading industry and non-industry players offering cell line characterization services?
  • What are the most popular services offered for characterization of cell lines?
  • Which partnership models are commonly adopted by stakeholders in this industry?
  • How is the current and future opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to cell line development and characterization market?

Chapter Outlines:

Chapter 2 is an executive summary of the insights captured in our research. The summary offers a high-level view on the likely evolution of the cell line development and characterization services market in the mid to long term.

Chapter 3 provides a general introduction to cell cultures and cell lines, including details related to various types of cell lines, based on their sources of origin, and key characteristics, applications and concerns associated with their use in drug development and research. The chapter also elaborates the recombinant and hybridoma cell line development process workflow. Further, it outlines the general concepts of cell line characterization along with a detailed description of different types of testing methods used for such purposes. In addition, it also presents the advantages and associated risks related to outsourcing of cell line development and characterization operations. In this chapter, we have briefly discussed the most common services offered by the service providers, along with cell line development and characterization services.

Chapter 4 provides an overview of the overall cell line development services landscape. It includes information related to over 220 contract service providers that are currently active in this domain. It features an in-depth analyses of the market, information on year of establishment, company size, location of headquarters, sources of cell lines and expression systems offered (mammalian, microbial, insect and avian), integrated cell line characterization, biosimilar cell line development and gene editing cell line development services offered, gene delivery method used (physical, chemical, biological and non-biological), type of gene expression (stable and transient), usage of serum-free / animal component free cell culture media, types of cell cultures (suspension and mixed growth properties), types of cells offered (recombinant, hybridoma and primary), applications of cell lines (R&D, biomanufacturing, diagnostics and cell therapy / regenerative medicine / tissue culture). In addition, the chapter includes information on additional cell line related services (bio-analytical / protein purification, cell banking, cell bank characterization, process development, GMP manufacturing and fill-finish), types of cell banks developed (master cell banks, working cell banks, research cell banks and end-of-production cell banks) and protein yield from cell lines.

Chapter 5 provides an insightful competitiveness analysis of the cell line development service providers that we came across during our research. The analysis compares the companies on the basis of supplier strength (experience of the service provider) and service portfolio strength (considering sources of cell lines and expression systems offered, availability of proprietary / licensed technology platform, type of gene expression and availability of additional cell line related services).

Chapter 6 features detailed profiles of some of the key players that are active in the cell line development domain. Each profile presents a brief overview of the company, its cell line development and complementary services portfolio, financial information (if available), recent developments and an informed future outlook.

Chapter 7 provides an overview of the overall cell line characterization services landscape. It includes information related to over 140 industry and non-industry contract service providers that are currently active in this domain. It features in-depth analyses of the market, based on a number of relevant parameters, such as year of establishment, company size, location of headquarters, types of cells handled (mammalian, microbial, insect and others), types of cell line characterization services offered (identity / stability testing, sterility / biosafety testing, expression testing and oncogenicity / tumorigenicity testing), types of cell line identity / stability testing services offered (analysis of cell morphology, cytochrome c oxidase 1 barcoding assay, DNA fingerprinting / profiling, gene copy number analysis, isozyme analysis, karyotype analysis, nucleic acid sequencing, southern blotting and viability testing) types of sterility / biosafety testing services offered (mycoplasma contamination testing, microbial contamination testing, viral / adventitious agents contamination testing, retroviral contamination testing and rodent virus testing / in-vivo biosafety testing), availability of other cell line related services (cell line development, cell banking and mycoplasma clearance service), information on regulatory accreditations / certifications and overall turnaround time. For non-industry players, the report features additional information on number of STR loci amplified, type of genotyping kit used and service fee charged.

Chapter 8 provides an insightful competitiveness analysis of the cell line characterization service providers that we came across during our research. The analysis compares the companies on the basis of supplier strength (in terms of experience of the service provider) and service portfolio strength (considering sources of cell lines and expression systems handled and size of the service portfolio).

Chapter 9 features detailed profiles of some of the key players that are active in the cell line characterization domain. Each profile presents a brief overview of the company, its cell line characterization services portfolio, financial information (if available), recent developments and an informed future outlook.

Chapter 10 features an in-depth analysis and discussion on the various partnerships that have been inked between the players in the cell line development and characterization market in the time period between 2015 and 2020 (till September). It includes a brief description of partnership models (such as technology platform utilization agreements, R&D collaborations, licensing agreements, mergers and acquisitions, product development and / or commercialization agreements, process development agreements, clinical trial agreements and other relevant deals) adopted by the stakeholders.

Chapter 11 features detailed profiles of the biorepositories across the globe that play an important role in developing cell lines and have also undertaken initiatives to limit the use of contaminated and / or misidentified cell lines. Each profile features a brief overview of the repository and its cell line characterization service portfolio.

Chapter 12 presents an elaborate discussion on the requirements defined by various regulatory authorities, across different regions, related to the characterization of cell lines. In addition, it provides insights from the various guideline documents that have been issued by these bodies on protocols that need to be followed and general tips for the testing of cell lines. It also features a brief historical overview and discussion on the contributions of key institutes / organizations involved in this domain.

Chapter 13 presents a comprehensive market forecast analysis, highlighting the likely growth of cell line development services market till the year 2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of sources of cell lines / expression systems (mammalian, microbial, insect and avian), applications of cell lines (R&D operations and drug development), company size (small, mid-sized and large) and key geographical regions (North America, Europe, Asia, Oceania and Rest of the World).

Chapter 14 presents a comprehensive market forecast analysis, highlighting the likely growth of cell line characterization services market till the year 2030. In order to provide a detailed future outlook, our projections have been segmented on the basis of sources of cell lines (mammalian, microbial and others), applications of cell lines (R&D operations and drug development), type of player (industry and non-industry) and key geographies (North America, Europe, Asia, Middle East & North Africa (MENA), Latin America (LATAM), Rest of the World (RoW)).

Chapter 15 is a collection of interview transcripts of the discussions held with key stakeholders in the industry. We have presented details of interviews held with Fai Poon (Founder and President, Quacell Biotechnology), Louis Boon (Chief Scientific Officer, Polpharma Biologics), Fan Chen (Former Vice President BioProcessing, LakePharma), Michael Pointek (Founder and Managing Director, ARTES Biotechnology), Nienke Smits (Client Relations Manager, Immunoprecise Antibodies) and Oscar Hoogteijling (Former Global Business Development Manager, Polpharma Biologics).

Chapter 16 presents insights from the survey conducted for this study. The participants, who were primarily Directors / CXO level representatives, helped us develop a deeper understanding on the nature of their services and their associated commercial potential.

Chapter 17 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario.

Chapter 18 is an appendix, which provides tabulated data and numbers for all the figures in the report.

Chapter 19 is an appendix, which provides the list of companies and organizations mentioned in the report.

Table of Contents

TABLE OF CONTENTS

1. PREFACE

  • 1.1. Scope of the Report
  • 1.2. Key Questions Answered
  • 1.3. Research Methodology
  • 1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION

  • 3.1. Chapter Overview
  • 3.2. Overview of Cell Culture
    • 3.2.1. Types of Cell Cultures by Origin
      • 3.2.1.1. Primary Cell Cultures
      • 3.2.1.2. Secondary Cell Cultures
    • 3.2.2. Types of Cell Cultures by Growth Properties
      • 3.2.2.1. Adherent Cell Cultures
      • 3.2.2.2. Suspension Cell Cultures
    • 3.2.3. Classification by Types of Cell Lines
      • 3.2.3.1. Finite Cell Lines
      • 3.2.3.2. Continuous Cell Lines
      • 3.2.3.3. Recombinant Cell Lines
      • 3.2.3.4. Hybridoma Cell Lines
    • 3.3.4. Classification by Sources of Cell Lines
      • 3.3.4.1. Mammalian Cell Lines
      • 3.3.4.2. Non-Mammalian Cell Lines
  • 3.5. Overview of Cell Line Development
    • 3.5.1. Recombinant Cell Line Development
      • 3.5.1.1. Vector Construction
      • 3.5.1.2. Transgene Delivery into Host Cells
      • 3.5.1.3. Cell Line Selection and Gene Amplification
      • 3.5.1.4. Clone Selection
      • 3.5.1.5. Stability Studies
    • 3.6.2. Hybridoma Cell Line Development
  • 3.7. Overview of Cell Line Characterization
    • 3.7.1. Identity Testing
      • 3.7.1.1. Karyotype Analysis
      • 3.7.1.2. Isozyme Analysis
      • 3.7.1.3. Cytochrome C Oxidase 1 Barcoding Assay
      • 3.7.1.4. Phenotype Analysis
      • 3.7.1.5. DNA Fingerprinting
      • 3.7.1.6. DNA Profiling
    • 3.8.2. Genetic Stability Testing
    • 3.8.3. Sterility / Biosafety Testing
    • 3.3.1. Mycoplasma Contamination Testing
      • 3.6.3.2. Viral Contamination Testing
      • 3.6.3.3. Other Sterility Testing Methods
  • 3.7. Additional Cell Line Related Services
    • 3.7.1. Cell Banking
      • 3.7.1.1. Classification of Cell Banks
    • 3.7.2. Process Development
      • 3.7.2.1. Upstream Process Development
      • 3.7.2.2. Downstream Process Development
    • 3.7.3. cGMP Manufacturing
  • 3.8. Applications of Cell Lines
  • 3.9. Factors Affecting the Quality of Cell Lines
  • 3.10. Need for Outsourcing Cell Line Related Operations

4. CELL LINE DEVELOPMENT SERVICE PROVIDERS: MARKET LANDSCAPE

  • 4.1. Chapter Overview
  • 4.2. Cell Line Development Service Providers: List of Players
    • 4.2.1. Analysis by Year of Establishment
    • 4.2.2. Analysis by Company Size
    • 4.2.3. Analysis by Location of Headquarters
    • 4.2.4. Analysis by Source of Cell Line and Expression System Offered
    • 4.2.5. Analysis by Types of Services Offered
      • 4.2.5.1. Integrated Cell Line Characterization
      • 4.2.5.2. Biosimilar Cell Line Development
      • 4.2.5.3. Genetically Modified Cell Line Development
    • 4.2.6. Analysis by Gene Delivery Method Used
    • 4.2.7. Analysis by Type of Gene Expression
    • 4.2.8. Analysis by Availability of Serum-Free / Animal Component Free Culturing Capabilities
    • 4.2.9. Analysis by Types of Cell Cultures
    • 4.2.10. Analysis by Types of Cells
    • 4.2.11. Analysis by Applications of Cell Lines
    • 4.2.12. Analysis by Availability of Additional Cell Line Related Services
    • 4.2.13. Analysis by Type of Cell Bank(s) Developed
    • 4.2.14. Geographical Presence Analysis of Companies (offering multiple cell lines) by Sources of Cell Lines and Company Size
      • 4.2.14.1. North America
      • 4.2.14.2. Europe
      • 4.2.14.3. Asia-Pacific
    • 4.2.15. Geographical Presence Analysis of Companies (offering a single cell line) by Source of Cell Line and Company Size
    • 4.2.16. Heat Map Analysis: Analysis by Year of Establishment, Location of Headquarters and Additional Cell Line Related Services
    • 4.2.17. Heat Map Analysis: Distribution by Location of Headquarters and Combinations of Sources of Cell Lines Offered
    • 4.2.18. Information on Protein Yield from Cell Lines

5. CELL LINE DEVELOPMENT SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS

  • 5.1. Chapter Overview
  • 5.2. Methodology
  • 5.3. Assumptions / Key Parameters
    • 5.3.1. Company Competitiveness Analysis: Cell Line Development Service Providers in North America
    • 5.3.2. Company Competitiveness Analysis: Cell Line Development Service Providers in Europe
    • 5.3.3. Company Competitiveness Analysis: Cell Line Development Service Providers in Asia-Pacific
  • 5.4. Summary

6. COMPANY PROFILES: CELL LINE DEVELOPMENT SERVICE PROVIDERS

  • 6.1. Chapter Overview
  • 6.2. Cell Line Development Service Providers: North America
    • 6.2.1. Creative Biogene
      • 6.2.1.1. Company Overview
      • 6.2.1.2. Service Portfolio
      • 6.2.1.3. Recent Developments and Future Outlook
    • 6.2.2. Creative Biolabs
      • 6.2.2.1. Company Overview
      • 6.2.2.2. Service Portfolio
      • 6.2.2.3. Recent Developments and Future Outlook
    • 6.2.3. Hyprocell
      • 6.2.3.1. Company Overview
      • 6.2.3.2. Service Portfolio
      • 6.2.3.3. Recent Developments and Future Outlook
    • 6.2.4. LakePharma
      • 6.2.4.1. Company Overview
      • 6.2.4.2. Service Portfolio
      • 6.2.4.3. Recent Developments and Future Outlook
    • 6.2.5. Thermo Fisher Scientific
      • 6.2.5.1. Company Overview
      • 6.2.5.2. Financial Information
      • 6.2.5.3. Service Portfolio
      • 6.2.5.4. Recent Developments and Future Outlook
  • 6.3. Cell Line Development Service Providers: Europe
    • 6.3.1. FUJIFILM Diosynth Biotechnologies
      • 6.3.1.1. Company Overview
      • 6.3.1.2. Service Portfolio
      • 6.3.1.3. Recent Developments and Future Outlook
    • 6.3.2. Lonza
      • 6.3.2.1. Company Overview
      • 6.3.2.2. Financial Information
      • 6.3.2.3. Service Portfolio
      • 6.3.2.4. Recent Developments and Future Outlook
    • 6.3.3. ProBioGen
      • 6.3.3.1. Company Overview
      • 6.3.3.2. Service Portfolio
      • 6.3.3.3. Recent Developments and Future Outlook
    • 6.3.4. Polpharma Biologics
      • 6.3.4.1. Company Overview
      • 6.3.4.2. Service Portfolio
      • 6.3.4.3. Recent Developments and Future Outlook
    • 6.3.5. Selexis
      • 6.3.5.1. Company Overview
      • 6.3.5.2. Service Portfolio
      • 6.3.5.3. Recent Developments and Future Outlook
  • 6.4. Cell Line Development Service Providers: Asia-Pacific
    • 6.4.1. Detai Bio-Tech
      • 6.4.1.1. Company Overview
      • 6.4.1.2. Service Portfolio
      • 6.4.1.3. Recent Developments and Future Outlook
    • 6.4.2. WuXi Biologics
      • 6.4.2.1. Company Overview
      • 6.4.2.2. Financial Information
      • 6.4.2.3. Service Portfolio
      • 6.4.2.4. Recent Developments and Future Outlook

7. CELL LINE CHARACTERIZATION SERVICE PROVIDERS: MARKET LANDSCAPE

  • 7.1. Chapter Overview
  • 7.2. Cell Line Characterization Service Providers: Overall Market Landscape
    • 7.2.1. Cell Line Characterization Service Providers: Industry Players
      • 7.2.1.1. Analysis by Year of Establishment
      • 7.2.1.2. Analysis by Company Size
      • 7.2.1.3. Analysis by Location of Headquarters
      • 7.2.1.4. Analysis by Types of Cells Handled
      • 7.2.1.5. Analysis by Type of Cell Line Characterization Service(s) Offered
      • 7.2.1.6. Analysis by Type of Cell Line Identity / Stability Testing Service(s) Offered
      • 7.2.1.7. Analysis by Type of Sterility / Biosafety Testing Service(s) Offered
      • 7.2.1.8. Analysis by Availability of Additional Cell Line Related Services
      • 7.2.1.9. Geographical Presence Analysis of Companies (offering multiple cell lines) by Location of Headquarters
    • 7.2.2. Cell Line Characterization Service Providers: Non-Industry Players
      • 7.2.2.1. Analysis by Service Location
      • 7.2.2.2. Analysis by Types of Cells Handled
      • 7.2.2.3. Analysis by Type of Cell Line Characterization Service(s) Offered
      • 7.2.2.4. Analysis by Number of STR Loci Amplified
      • 7.2.2.5. Analysis by Type of Genotyping Kit(s) Used

8. CELL LINE CHARACTERIZATION SERVICE PROVIDERS: COMPANY COMPETITIVENESS ANALYSIS

  • 8.1. Chapter Overview
  • 8.2. Methodology
  • 8.3. Assumptions / Key Parameters
    • 8.3.1. Company Competitiveness Analysis: Cell Line Characterization Service Providers in North America
    • 8.3.2. Company Competitiveness Analysis: Cell Line Characterization Service Providers in Europe
    • 8.3.3. Company Competitiveness Analysis: Cell Line Characterization Service Providers in Asia-Pacific
  • 8.4. Summary

9. COMPANY PROFILES: CELL LINE CHARACTERIZATION SERVICE PROVIDERS

  • 9.1. Chapter Overview
  • 9.2. Cell Line Characterization Service Providers: North America
    • 9.2.1. BioReliance
      • 9.2.1.1. Company Overview
      • 9.2.1.2. Service Portfolio
      • 9.2.1.3. Recent Developments and Future Outlook
    • 9.2.2. Charles River Laboratories
      • 9.2.2.1. Company Overview
      • 9.2.2.3. Financial Information
      • 9.2.2.2. Service Portfolio
      • 9.2.2.3. Recent Developments and Future Outlook
    • 9.2.3. Molecular Diagnostic Services
      • 9.2.3.1. Company Overview
      • 9.2.3.2. Service Portfolio
      • 9.2.3.3. Recent Developments and Future Outlook
  • 9.3. Cell Line Characterization Service Providers: Europe
    • 9.3.1. Eurofins BioPharma Product Testing
      • 9.3.1.1. Company Overview
      • 9.3.1.2. Service Portfolio
      • 9.3.1.3. Recent Developments and Future Outlook
    • 9.3.2. Sartorius Stedim Biotech
      • 9.3.2.1. Company Overview
      • 9.3.2.2. Financial Information
      • 9.3.2.3. Service Portfolio
      • 9.3.2.4. Recent Developments and Future Outlook
    • 9.3.3. SGS
      • 9.3.3.1. Company Overview
      • 9.3.3.2. Service Portfolio
      • 9.3.3.3. Recent Developments and Future Outlook
  • 9.4. Cell Line Characterization Service Providers: Asia-Pacific
    • 9.4.1. LivoGen Pharmed
      • 9.4.1.1. Company Overview
      • 9.4.1.2. Service Portfolio
      • 9.4.1.3. Recent Developments and Future Outlook
    • 9.4.2. TFBS Bioscience
      • 9.4.2.1. Company Overview
      • 9.4.2.2. Service Portfolio
      • 9.4.2.3. Recent Developments and Future Outlook

10. PARTNERSHIPS AND COLLABORATIONS

  • 10.1. Chapter Overview
  • 10.2. Partnership Models
  • 10.3. Cell Line Development and Characterization Service Providers: List of Partnerships and Collaborations
  • 10.4. Analysis by Year of Partnership
  • 10.5. Analysis by Type of Partnership
  • 10.6. Analysis by Types of Cells Involved
  • 10.7. Analysis by Type of Technology Platform Used
  • 10.8. Analysis by Type of Indication
  • 10.9. Analysis by Year of Partnership and Type of Partner
  • 10.10. Analysis by Type of Partnership and Type of Partner
  • 10.11. Most Active Players: Analysis by Number of Partnerships
  • 10.12. Regional Analysis
  • 10.13. Intercontinental and Intracontinental Agreements

11. CELL LINE REPOSITORIES

  • 11.1. Chapter Overview
  • 11.2. American Type Culture Collection (ATCC)
    • 11.2.1. Overview
    • 11.2.2. Service Portfolio
  • 11.3. European Collection of Authenticated Cell Cultures (ECACC)
    • 11.3.1. Overview
    • 11.3.2. Service Portfolio
  • 11.4. Leibniz Institute DSMZ
    • 11.4.1. Overview
    • 11.4.2. Service Portfolio
  • 11.5. Coriell Institute for Medical Research
    • 11.5.1. Overview
      • 11.5.1.1. Service Portfolio

12. REGULATORY RECOMMENDATIONS AND GUIDELINES

  • 12.1. Chapter Overview
  • 12.2. History of Cell Line Authentication
  • 12.3. Cell Line Authentication: Prominent Regulatory Authorities
    • 12.3.1. Role of American Type Culture Collection (ATCC)
    • 12.3.2. Role of International Cell Line Authentication Committee (ICLAC)
    • 12.3.3. Role of Global Biological Standards Institute (GBSI)
  • 12.4. Guidelines Issued by International Regulatory Agencies for Cell Line Characterization
    • 12.4.1. World Health Organization (WHO)
    • 12.4.2. The International Council for Harmonisation (ICH) of Technical Requirements for Pharmaceuticals for Human Use
  • 12.5. Regulatory Guidelines for Cell Line Characterization in the US
  • 12.6. Regulatory Guidelines for Cell Line Characterization in Europe
  • 12.7. Regulatory Guidelines for Cell Line Characterization in Japan

13. CELL LINE DEVELOPMENT SERVICES: MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 13.1. Chapter Overview
  • 13.2. Forecast Methodology and Key Assumptions
  • 13.3. Overall Cell Line Development Services Market, 2020-2030
  • 13.4. Cell Line Development Services Market, 2020-2030: Distribution by Sources of Cell Lines and Expression Systems Used
  • 13.5. Cell Line Development Services Market, 2020-2030: Distribution by Applications
  • 13.6. Cell Line Development Services Market, 2020-2030: Distribution by Company Size
  • 13.7. Cell Line Development Services Market, 2020-2030: Distribution by Geography
    • 13.7.1. Cell Line Development Services Market in North America, 2020-2030
      • 13.7.1.1. Cell Line Development Services Market in North America, 2020-2030: Share of Small-sized Companies
      • 13.7.1.2. Cell Line Development Services Market in North America, 2020-2030: Share of Mid-sized Companies
      • 13.7.1.3. Cell Line Development Services Market in North America, 2020-2030: Share of Large Companies
      • 13.7.1.4. Cell Line Development Services Market in North America, 2020-2030: Share of Research and Development Operations
      • 13.7.1.5. Cell Line Development Services Market in North America, 2020-2030: Share of Drug Development Operations
    • 13.7.2. Cell Line Development Services Market in Europe, 2020-2030
      • 13.7.2.1. Cell Line Development Services Market in Europe, 2020-2030: Share of Small-sized Companies
      • 13.7.2.2. Cell Line Development Services Market in Europe, 2020-2030: Share of Mid-sized Companies
      • 13.7.2.3. Cell Line Development Services Market in Europe, 2020-2030: Share of Large Companies
      • 13.7.2.4. Cell Line Development Services Market in Europe, 2020-2030: Share of Research and Development Operations
      • 13.7.2.5. Cell Line Development Services Market in Europe, 2020-2030: Share of Drug Development Operations
    • 13.7.2. Cell Line Development Services Market in Asia, 2020-2030
      • 13.7.2.1. Cell Line Development Services Market in Asia, 2020-2030: Share of Small-sized Companies
      • 13.7.2.2. Cell Line Development Services Market in Asia, 2020-2030: Share of Mid-sized Companies
      • 13.7.2.3. Cell Line Development Services Market in Asia, 2020-2030: Share of Large Companies
      • 13.7.2.4. Cell Line Development Services Market in Asia, 2020-2030: Share of Research and Development Operations
      • 13.7.2.5. Cell Line Development Services Market in Asia, 2020-2030: Share of Drug Development Operations
    • 13.7.3. Cell Line Development Services Market in Oceania, 2020-2030
      • 13.7.3.1. Cell Line Development Services Market in Oceania, 2020-2030: Share of Small-sized Companies
      • 13.7.3.2. Cell Line Development Services Market in Oceania, 2020-2030: Share of Mid-sized Companies
      • 13.7.3.3. Cell Line Development Services Market in Oceania, 2020-2030: Share of Large Companies
      • 13.7.3.4. Cell Line Development Services Market in Oceania, 2020-2030: Share of Research and Development Operations
      • 13.7.3.5. Cell Line Development Services Market in Oceania, 2020-2030: Share of Drug Development Operations
    • 13.7.4. Cell Line Development Services Market in Rest of the World, 2020-2030
      • 13.7.4.1. Cell Line Development Services Market in Rest of the World, 2020-2030: Share of Small-sized Companies
      • 13.7.4.2. Cell Line Development Services Market in Rest of the World, 2020-2030: Share of Mid-sized Companies
      • 13.7.4.3. Cell Line Development Services Market in Rest of the World, 2020-2030: Share of Large Companies
      • 13.7.4.4. Cell Line Development Services Market in Rest of the World, 2020-2030: Share of Research and Development Operations
      • 13.7.4.5. Cell Line Development Services Market in Rest of the World, 2020-2030: Share of Drug Development Operations

14. CELL LINE CHARACTERIZATION SERVICES: MARKET SIZING AND OPPORTUNITY ANALYSIS

  • 14.1. Chapter Overview
  • 14.2. Forecast Methodology and Key Assumptions
  • 14.3. Overall Cell Line Characterization Services Market, 2020-2030
  • 14.4. Cell Line Characterization Services Market, 2020-2030: Distribution by Sources of Cell Lines
  • 14.5. Cell Line Characterization Services Market, 2020-2030: Distribution by Geography
  • 14.6. Cell Line Characterization Services Market, 2020-2030: Distribution by Type of Industry
  • 14.7. Cell Line Characterization Services Market, 2020-2030: Distribution by Stage of Development of Biologics

15. EXECUTIVE INSIGHTS

  • 15.1. Chapter Overview
  • 15.2. Northway Biotech
    • 15.2.1. Company Snapshot
    • 15.2.2. Interview Transcript: Virgilijus Kupinas, Marketing and Business Development Coordinator (Q4 2020)
  • 15.3. QuaCell Biotechnology
    • 15.3.1. Company Snapshot
    • 15.3.2. Interview Transcript: Fai Poon, Founder and President (Q3 2020)
  • 15.4. Polpharma Biologics
    • 15.4.1. Company Snapshot
    • 15.4.2. Interview Transcript: Louis Boon, Chief Scientific Officer (Q3 2020)
  • 15.5. LakePharma
    • 15.5.1. Company Snapshot
    • 15.5.2. Interview Transcript: Fan Chen, Former Vice President BioProcessing (Q3 2017)
  • 15.6. ARTES Biotechnology
    • 15.6.1. Company Snapshot
    • 15.6.2. Interview Transcript: Michael Pointek, Founder and Managing Director (Q3 2017)
  • 15.7. ImmunoPrecise Antibodies
    • 15.7.1. Company Snapshot
    • 15.7.2. Interview Transcript: Nienke Smits, Client Relations Manager (Q3 2017)
  • 15.8. Bioceros (acquired by Polpharma Biologics)
    • 15.8.1. Interview Transcript: Oscar Hoogteijling, Former Global Business Development Manager (Q3 2017)

16. SURVEY ANALYSIS

  • 16.1. Chapter Overview
  • 16.2. Overview of Respondents
  • 16.3. Designation of Respondents
  • 16.4. Survey Insights
    • 16.4.1. Type of Cell Line Offered
    • 16.4.2. Source of Cell Line
    • 16.4.3. Applications of Cell Lines
    • 16.4.4. Cell Line Characterization Services
    • 16.4.5. Cell Banking Services
    • 16.4.6. Biologics Manufacturing Services
    • 16.4.7. Fill / Finish Services

17. CONCLUDING REMARKS

  • 17.1. Chapter Overview
  • 17.2. Key Takeaways

18. APPENDIX 1: TABULATED DATA

19. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List Of Figures

  • Figure 3.1 Primary and Secondary Cell Cultures
  • Figure 3.2 Initiation of Cell Cultures
  • Figure 3.3 Recombinant Cell Line Development: Process Workflow
  • Figure 3.4 Hybridoma Cell Line Development: Process Workflow
  • Figure 3.5 Sources of Non-Mammalian Cell Lines
  • Figure 3.6 Testing Methods for Cell Line Characterization
  • Figure 3.7 Karyotype Preparation: Process Workflow
  • Figure 3.8 DNA Hybridization: Process Workflow
  • Figure 3.9 DNA Fingerprinting: Process Workflow
  • Figure 3.10 DNA Fingerprinting: Process Workflow
  • Figure 3.11 Master and Working Cell Banks Production: Process Workflow
  • Figure 3.12 Cell Line Development in Overall Biomanufacturing Process
  • Figure 3.13 Applications of Cell Lines
  • Figure 3.14 Factors Affecting the Quality of Cell Lines
  • Figure 3.15 Advantages and Risks Associated with Outsourcing of Cell Line Related Operations
  • Figure 4.1 Cell Line Development Service Providers: Distribution by Year of Establishment
  • Figure 4.2 Cell Line Development Service Providers: Distribution by Company Size
  • Figure 4.3 Cell Line Development Service Providers: Distribution by Location of Headquarters
  • Figure 4.4 World Map Representation: Analysis by Geography
  • Figure 4.5 Cell Line Development Service Providers: Distribution by Sources of Cell Lines and Expression Systems Offered
  • Figure 4.6 Cell Line Development Service Providers Offering Multiple Cell Lines in North America: Distribution by Sources of Cell Lines and Company Size
  • Figure 4.7 Cell Line Development Service Providers Multiple Cell Lines in Europe: Distribution by Sources of Cell Lines and Company Size
  • Figure 4.8 Cell Line Development Service Providers Offering Multiple Cell Lines in Asia-Pacific: Distribution by Sources of Cell Lines and Company Size
  • Figure 4.9 Cell Line Development Service Providers Offering Single Cell Line: Distribution by Sources of Cell Lines and Company Size
  • Figure 4.10 Cell Line Development Service Providers: Distribution by Availability of Integrated Cell Line Characterization Service
  • Figure 4.11 Cell Line Development Service Providers: Distribution by Availability of Integrated Biosimilar Cell Line Development Service
  • Figure 4.12 Cell Line Development Service Providers: Distribution by Availability of Gene Editing Cell Line Development Service
  • Figure 4.13 Cell Line Development Service Providers: Distribution by Gene Delivery Methods Used
  • Figure 4.14 Cell Line Development Service Providers: Distribution by Type of Gene Expression
  • Figure 4.15 Cell Line Development Service Providers: Distribution by Usage of Serum-free / Animal Component Free Media
  • Figure 4.16 Cell Line Development Service Providers: Distribution by Types of Cell Cultures
  • Figure 4.17 Cell Line Development Service Providers: Distribution by Types of Cells Offered
  • Figure 4.18 Cell Line Development Service Providers: Distribution by Applications of Cell Lines
  • Figure 4.19 Cell Line Development Service Providers: Distribution by Types of Additional Cell Line Related Services Offered
  • Figure 4.20 Cell Line Development Service Providers: Distribution by Type of Cell Bank(s)
  • Figure 4.21 Heat Map Analysis: Analysis by Year of Establishment, Location of Headquarters and Cell Line Related Services
  • Figure 4.22 Heat Map Analysis: Distribution by Location of Headquarters and Sources of Cell Lines Offered
  • Figure 5.1 Company Competitiveness: Cell Line Development Service Providers in North America
  • Figure 5.2 Company Competitiveness: Cell Line Development Service Providers in Europe
  • Figure 5.3 Company Competitiveness: Cell Line Development Service Providers in Asia-Pacific
  • Figure 5.4 Company Competitiveness: Top Cell Line Development Service Providers
  • Figure 6.1 Thermo Fisher Scientific: Annual Revenues, FY 2015-H1 2020 (EUR Billion)
  • Figure 6.2 Lonza: Annual Revenues, FY 2015-H1 2020 (CHF Billion)
  • Figure 6.3 WuXi Biologics: Annual Revenues, FY 2016-H1 2020 (RMB Billion)
  • Figure 7.1 Cell Line Characterization Service Providers: Overall Market Landscape
  • Figure 7.2 Cell Line Characterization Service Providers (Industry Players): Distribution by Year of Establishment
  • Figure 7.3 Cell Line Characterization Service Providers (Industry Players): Distribution by Company Size
  • Figure 7.4 Cell Line Characterization Service Providers (Industry Players): Distribution by Location of Headquarters
  • Figure 7.5 World Map Representation: Analysis by Geography
  • Figure 7.6 Cell Line Characterization Service Providers (Industry Players): Distribution by Types of Cells Handled
  • Figure 7.7 Cell Line Development Service Providers (Industry Players): Distribution of Companies Offering Multiple Cell Lines by Location of Headquarters
  • Figure 7.8 Cell Line Development Service Providers (Industry Players): Distribution by Type of Cell Line Characterization Service(s) Offered
  • Figure 7.9 Cell Line Characterization Service Providers (Industry Players): Type of Cell Line Identity / Stability Testing Service(s) Offered
  • Figure 7.10 Cell Line Characterization Service Providers (Industry Players): Type of Cell Line Sterility / Biosafety Testing Service(s) Offered
  • Figure 7.11 Cell Line Characterization Service Providers (Industry Players): Distribution by Availability of Additional Cell Line Related Services
  • Figure 7.12 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Location of Organization
  • Figure 7.13 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Types of Cells Handled
  • Figure 7.14 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Type of Cell Line Characterization Service(s) Offered
  • Figure 7.15 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Type of Genotyping Kit(s) Used
  • Figure 7.16 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Number of STR Loci Amplified
  • Figure 8.1 Company Competitiveness: Cell Line Characterization Service Providers in North America
  • Figure 8.2 Company Competitiveness: Cell Line Characterization Service Providers in Europe
  • Figure 8.3 Company Competitiveness: Cell Line Characterization Service Providers in Asia-Pacific
  • Figure 8.4 Company Competitiveness: Top Cell Line Characterization Service Providers
  • Figure 9.1 Charles River Laboratories: Annual Revenues, FY 2015-Q1-Q3 2020 (USD Million)
  • Figure 9.2 Sartorius Stedim Biotech, Annual Revenues, FY 2016-H1 2020 (EUR Million)
  • Figure 9.3 SGS: Annual Revenues, FY 2015-H1 2020 (CHF Million)
  • Figure 10.1 Partnerships and Collaborations: Partnerships and Collaborations: Cumulative Trend by Year of Partnership, 2015-2020
  • Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
  • Figure 10.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership (2015-2020)
  • Figure 10.4 Partnerships and Collaborations: Distribution by Type of Product being Licensed
  • Figure 10.5 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
  • Figure 10.6 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Figure 10.7 Most Active Players: Distribution by Number of Partnerships
  • Figure 10.8 Partnerships and Collaborations: Regional Distribution
  • Figure 10.9 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
  • Figure 10.10 Most Popular Technology Platform: Distribution by Number of Partnerships
  • Figure 10.11 Partnerships and Collaborations: Distribution by Types of Cells Involved
  • Figure 10.12 Partnerships and Collaborations: Distribution by Type of Target Disease Indication
  • Figure 11.1 ATCC: Service Portfolio
  • Figure 11.2 ECACC: Biological Material Collection
  • Figure 11.3 ECACC: Service Portfolio
  • Figure 11.4 Leibniz Institute DSMZ: Biological Material Collection
  • Figure 11.5 Coriell Institute of Medical Research: Operating Segments
  • Figure 11.6 Coriell Institute for Medical Research: Service Portfolio
  • Figure 12.1 ICH Q5A (R1) Guidelines: Cell Bank Qualification
  • Figure 12.2 ICH Q5D Guidelines: Cell Bank Characterization
  • Figure 12.3 FDA Guidelines: Cell Bank Qualification
  • Figure 12.4 USP 63: Mycoplasma Detection in Cell Banks
  • Figure 12.5 CFR 610.18: Recommendations for Testing of Cell Lines
  • Figure 12.6 CFR 113.52: Recommendations for Testing of Cell Banks
  • Figure 12.7 EP 2.6.7: Recommendations for Mycoplasma Testing of Cell Banks
  • Figure 12.8 JP: Recommendations for Mycoplasma Testing of Cell Banks
  • Figure 13.1 Global Cell Line Development Services Market: 2020-2030 (USD Million)
  • Figure 13.2 Global Cell Line Development Services Market: Distribution by Sources of Cell Lines, 2020 and 2030 (USD Million)
  • Figure 13.3. Cell Line Development Services Market for Mammalian Cell Lines, 2020-2030 (USD Million)
  • Figure 13.4 Cell Line Development Services Market for Microbial Cell Lines, 2020-2030 (USD Million)
  • Figure 13.5 Cell Line Development Services Market for Insect Cell Lines, 2020-2030 (USD Million)
  • Figure 13.6 Cell Line Development Services Market for Avian Cell Lines, 2020-2030 (USD Million)
  • Figure 13.7 Global Cell Line Development Services Market: Distribution by Applications of Cell Lines, 2020 and 2030 (USD Million)
  • Figure 13.8 Cell Line Development Services Market for Bioproduction, 2020-2030 (USD Million)
  • Figure 13.9 Cell Line Development Services Market for Research and Development Operations, 2020-2030 (USD Million)
  • Figure 13.10 Global Cell Line Development Services Market: Distribution by Company Size, 2020 and 2030 (USD Million)
  • Figure 13.11 Cell Line Development Services Market for Small Companies, 2020-2030 (USD Million)
  • Figure 13.12 Cell Line Development Services Market for Mid-sized Companies, 2020-2030 (USD Million)
  • Figure 13.13 Cell Line Development Services Market for Large Companies, 2020-2030 (USD Million)
  • Figure 13.14 Global Cell Line Development Services Market: Distribution by Geography, 2020 and 2030 (USD Million)
  • Figure 13.15 Cell Line Development Services Market in North America, 2020-2030 (USD Million)
  • Figure 13.16 Cell Line Development Services Market in Europe, 2020-2030 (USD Million)
  • Figure 13.17 Cell Line Development Services Market in Asia, 2020-2030 (USD Million)
  • Figure 13.18 Cell Line Development Services Market in Oceania, 2020-2030 (USD Million)
  • Figure 13.19 Cell Line Development Services Market in the Rest of the World, 2020 (USD Million)
  • Figure 14.1 Global Cell Line Characterization Services Market, 2020-2030 (USD Million)
  • Figure 14.2 Global Cell Line Characterization Services Market: Distribution by Types of Projects, 2020-2030 (USD Million)
  • Figure 14.3 Global Cell Line Characterization Services Market: Distribution by Sources of Cell Lines, 2020 and 2030 (USD Million)
  • Figure 14.4 Cell Line Characterization Services Market for Mammalian Cell Lines, 2020-2030 (USD Million)
  • Figure 14.5 Cell Line Characterization Services Market for Microbial Cell Lines, 2020-2030 (USD Million)
  • Figure 14.6 Cell Line Characterization Services Market for Other Cell Lines, 2020-2030 (USD Million)
  • Figure 14.7 Global Cell Line Characterization Services Market: Distribution by Applications of Cell Lines, 2020 and 2030 (USD Million)
  • Figure 14.8 Cell Line Characterization Services Market for Bioproduction, 2020-2030 (USD Million)
  • Figure 14.9 Cell Line Characterization Services Market for Research and Development Operations, 2020-2030 (USD Million)
  • Figure 14.10 Global Cell Line Characterization Services Market: Distribution by Type of Service Provider, 2020 and 2030 (USD Million)
  • Figure 14.11 Cell Line Characterization Services Market for Industry Players, 2020-2030 (USD Million)
  • Figure 14.12 Cell Line Characterization Services Market for Non-Industry Players, 2020-2030 (USD Million)
  • Figure 14.13 Global Cell Line Characterization Services Market: Distribution by Geography, 2020 and 2030 (USD Million)
  • Figure 14.14 Cell Line Characterization Services Market in the US, 2020-2030 (USD Million)
  • Figure 14.15 Cell Line Characterization Services Market in Canada, 2020-2030 (USD Million)
  • Figure 14.16 Cell Line Characterization Services Market in the UK, 2020-2030 (USD Million)
  • Figure 14.17 Cell Line Characterization Services Market in France, 2020-2030 (USD Million)
  • Figure 14.18 Cell Line Characterization Services Market in Germany, 2020-2030 (USD Million)
  • Figure 14.19 Cell Line Characterization Services Market in Spain, 2020-2030 (USD Million)
  • Figure 14.20 Cell Line Characterization Services Market in Italy, 2020-2030 (USD Million)
  • Figure 14.21 Cell Line Characterization Services Market in Rest of Europe, 2020-2030 (USD Million)
  • Figure 14.22 Cell Line Characterization Services Market in China, 2020-2030 (USD Million)
  • Figure 14.23 Cell Line Characterization Services Market in Japan, 2020-2030 (USD Million)
  • Figure 14.24 Cell Line Characterization Services Market in India, 2020-2030 (USD Million)
  • Figure 14.25 Cell Line Characterization Services Market in Latin America, 2020-2030 (USD Million)
  • Figure 14.26 Cell Line Characterization Services Market in Middle East and North Africa, 2020-2030 (USD Million)
  • Figure 14.27 Cell Line Characterization Services Market in the Rest of the World, 2020-2030 (USD Million)
  • Figure 16.1 Survey Analysis: Distribution by Location of Organization
  • Figure 16.2 Survey Analysis: Distribution by Location of Manufacturing Facilities
  • Figure 16.3 Survey Analysis: Distribution by Seniority Level of Respondents
  • Figure 16.4 Survey Analysis: Distribution by Types of Cell Lines
  • Figure 16.5 Survey Analysis: Distribution by Sources of Cell Lines
  • Figure 16.6 Survey Analysis: Distribution by Applications of Cell Lines
  • Figure 16.7 Survey Analysis: Cell Line Characterization Services
  • Figure 16.8 Survey Analysis: Cell Banking Services
  • Figure 16.9 Survey Analysis: Biologics Manufacturing Services
  • Figure 16.10 Survey Analysis: Fill / Finish Services
  • Figure 17.1 Concluding Remarks: Current Market Landscape of Cell Line Development Services
  • Figure 17.2 Concluding Remarks: Current Market Landscape of Cell Line Characterization Services
  • Figure 17.3 Concluding Remarks: Geographical Distribution of Cell Line Development and Characterization Service Providers
  • Figure 17.4 Concluding Remarks: Partnerships and Collaborations
  • Figure 17.5 Concluding Remarks: Cell Line Development Services Market Sizing and Opportunity Analysis
  • Figure 17.6 Concluding Remarks: Cell Line Characterization Services Market Sizing and Opportunity Analysis

List Of Tables

  • Table 3.1 Comparison between Finite and Continuous Cell Lines
  • Table 3.2 Popular Mammalian Cell Lines used in Biopharmaceutical Production
  • Table 3.3 Human Cell Lines and Therapeutic Protein Products
  • Table 3.4 Cell Lines and Viral Vaccine Products
  • Table 4.1 Cell Line Development Service Providers: List of Players
  • Table 4.2 Cell Line Development Service Providers: Information on Sources of Cell Lines and Expresion Systems Offered
  • Table 4.3 Cell Line Development Service Providers: Information on Technology and Service related Parameters
  • Table 4.4 Cell Line Development Service Providers: Information on Cell Line Development Process Related Parameters
  • Table 4.5 Cell Line Development Service Providers: Information on Types of Cells Offered and Applications of Cell Lines
  • Table 4.6 Cell Line Development Service Providers: Information on Additional Cell Line Related Services
  • Table 4.7 Cell Line Development Service Providers: Information on Yield / Amount of Protein Expressed from Cell Lines
  • Table 6.1 Cell Line Development Service Providers: List of Profiled Companies
  • Table 6.2 Creative Biogene: Company Snapshot
  • Table 6.3 Creative Biogene: Overview of Cell Line Development Services
  • Table 6.4 Creative Biogene: Recent Developments and Future Outlook
  • Table 6.5 Creative Biolabs: Company Snapshot
  • Table 6.6 Creative Biolabs: Overview of Cell Line Development Services
  • Table 6.7 Creative Biolabs: Recent Developments and Future Outlook
  • Table 6.8 Hyprocell: Company Snapshot
  • Table 6.9 Hyprocell: Overview of Cell Line Development Services
  • Table 6.10 Hyprocell: Recent Developments and Future Outlook
  • Table 6.11 LakePharma: Company Snapshot
  • Table 6.12 LakePharma: Overview of Cell Line Development Services
  • Table 6.13 LakePharma: Recent Developments and Future Outlook
  • Table 6.14 Thermo Fisher Scientific: Company Snapshot
  • Table 6.15 Thermo Fisher Scientific: Overview of Cell Line Development Services
  • Table 6.16 Thermo Fisher Scientific: Recent Developments and Future Outlook
  • Table 6.17 FUJIFILM Diosynth Biotechnologies: Company Snapshot
  • Table 6.18 FUJIFILM Diosynth Biotechnologies: Overview of Cell Line Development Services
  • Table 6.19 FUJIFILM Diosynth Biotechnologies: Recent Developments and Future Outlook
  • Table 6.20 Lonza: Company Snapshot
  • Table 6.21 Lonza: Overview of Cell Line Development Services
  • Table 6.22 Lonza: Recent Developments and Future Outlook
  • Table 6.23 ProBioGen: Company Snapshot
  • Table 6.24 ProBioGen: Overview of Cell Line Development Services
  • Table 6.25 ProBioGen: Recent Developments and Future Outlook
  • Table 6.26 Polpharma Biologics: Company Snapshot
  • Table 6.27 Polpharma Biologics: Overview of Cell Line Development Services
  • Table 6.28 Polpharma Biologics: Recent Developments and Future Outlook
  • Table 6.29 Selexis: Company Snapshot
  • Table 6.30 Selexis: Overview of Cell Line Development Services
  • Table 6.31 Selexis: Recent Developments and Future Outlook
  • Table 6.32 Detai Bio-Tech: Company Snapshot
  • Table 6.33 Detai Bio-Tech: Overview of Cell Line Development Services
  • Table 6.34 Detai Bio-Tech: Recent Developments and Future Outlook
  • Table 6.35 WuXi Biologics: Company Snapshot
  • Table 6.36 WuXi Biologics: Overview of Cell Line Development Services
  • Table 6.37 WuXi Biologics: Recent Developments and Future Outlook
  • Table 7.1 Cell Line Characterization Service Providers: List of Industry Players
  • Table 7.2 Cell Line Characterization Service Providers (Industry Players): Information of Types of Cells Handled
  • Table 7.3 Cell Line Characterization Service Providers (Industry Players): Type of Cell Line Characterization Service(s) Offered
  • Table 7.4 Cell Line Characterization Service Providers (Industry Players): Type of Cell Identity / Stability Testing Service(s) Offered
  • Table 7.5 Cell Line Characterization Service Providers (Industry Players): Type of Cell Sterility / Biosafety Testing Service(s) Offered
  • Table 7.6 Cell Line Characterization Service Providers (Industry Players): Information on Additional Cell Line Related Services
  • Table 7.7 Cell Line Characterization Service Providers (Industry Players): Information on Regulatory Accreditations / Certifications and Overall Turnaround Time
  • Table 7.8 Cell Line Characterization Service Providers: List of Non-Industry Players and Types of Cells Handled
  • Table 7.9 Cell Line Characterization Service Providers (Non-Industry Players): Information on Type of Cell Line Characterization Service(s) Offered
  • Table 7.10 Line Characterization Service Providers (Non-Industry Players): Information on Genotyping Testing Services Offered
  • Table 7.11 Cell Line Characterization Service Providers (Non-Industry Players): Information on Service Fee Charged and Overall Turnaround Time
  • Table 7.12 Cell Line Characterization Service Providers: List of Players Offering Primary Cell / Stem Cell Characterization
  • Table 9.1 Cell Line Characterization Service Providers: List of Profiled Companies
  • Table 9.2 BioReliance: Company Snapshot
  • Table 9.3 BioReliance: Overview of Cell Line Development Services
  • Table 9.4 BioReliance: Recent Developments and Future Outlook
  • Table 9.5 Charles River Laboratories: Company Snapshot
  • Table 9.7 Charles River Laboratories: Overview of Cell Line Development Services
  • Table 9.8 Charles River Laboratories: Recent Developments and Future Outlook
  • Table 9.9 Molecular Diagnostic Services: Company Snapshot
  • Table 9.10 Molecular Diagnostic Services: Overview of Cell Line Development Services
  • Table 9.11 Molecular Diagnostic Services: Recent Developments and Future Outlook
  • Table 9.12 Eurofins BioPharma Product Testing: Company Snapshot
  • Table 9.13 Eurofins BioPharma Product Testing: Overview of Cell Line Development Services
  • Table 9.14 Eurofins BioPharma Product Testing: Recent Developments and Future Outlook
  • Table 9.15 Sartorius Stedim Biotech: Company Snapshot
  • Table 9.16 Sartorius Stedim Biotech: Financial Information
  • Table 9.17 Sartorius Stedim Biotech: Overview of Cell Line Development Services
  • Table 9.18 Sartorius Stedim Biotech: Recent Developments and Future Outlook
  • Table 9.19 SGS: Company Snapshot
  • Table 9.20 SGS: Overview of Cell Line Development Services
  • Table 9.21 SGS: Recent Developments and Future Outlook
  • Table 9.22 LivoGen Pharmed: Company Snapshot
  • Table 9.23 LivoGen Pharmed: Overview of Cell Line Development Services
  • Table 9.24 LivoGen Pharmed: Recent Developments and Future Outlook
  • Table 9.25 TFBS Bioscience: Company Snapshot
  • Table 9.26 TFBS Bioscience: Overview of Cell Line Development Services
  • Table 9.27 TFBS Bioscience: Recent Developments and Future Outlook
  • Table 10.1 Cell Line Development and Service Providers: List of Partnerships and Collaborations
  • Table 11.1 ATCC: Overview
  • Table 11.2 ECACC: Overview
  • Table 11.3 DSMZ: Overview
  • Table 12.1 WHO Recommendations: Cell Bank Characterization
  • Table 12.2 Regulatory Documents for Cell Line Characterization in the US
  • Table 12.3 USP 1050: Virus Testing in Cell Banks
  • Table 12.4 EP 5.2.3: Testing in Cell Banks
  • Table 15.1 Company Snapshot: Laragen
  • Table 15.2 Company Snapshot: QuaCell biotechnology
  • Table 15.3 Company Snapshot: Polpharma Biologics
  • Table 15.4 Company Snapshot: LakePharma
  • Table 15.5 Company Snapshot: ARTES Biotechnology
  • Table 15.6 Company Snapshot: ImmunoPrecise Antibodies
  • Table 16.1 Survey Analysis: Distribution by Location of Organization
  • Table 16.2 Survey Analysis: Distribution by Location of Manufacturing Facilities
  • Table 16.3 Survey Analysis: Distribution by Seniority Level of Respondents
  • Table 16.4 Survey Analysis: Distribution by Types of Cell Lines
  • Table 16.5 Survey Analysis: Distribution by Sources of Cell Lines
  • Table 16.6 Survey Analysis: Distribution by Applications of Cell Lines
  • Table 16.7 Survey Analysis: Cell Line Characterization Services
  • Table 16.8 Survey Analysis: Cell Banking Services
  • Table 16.9 Survey Analysis: Biologics Manufacturing Services
  • Table 16.10 Survey Analysis: Fill / Finish Services
  • Table 18.1 Cell Line Development Service Providers: Distribution by Year of Establishment
  • Table 18.2 Cell Line Development Service Providers: Distribution by Company Size
  • Table 18.3 Cell Line Development Service Providers: Distribution by Location of Headquarters
  • Table 18.4 Cell Line Development Service Providers: Distribution by Geography
  • Table 18.5 Cell Line Development Service Providers: Distribution by Sources of Cell Lines and Expression Systems Offered
  • Table 18.6 Cell Line Development Service Providers: Distribution by Availability of Integrated Cell Line Characterization Service
  • Table 18.7 Cell Line Development Service Providers: Distribution by Availability of Biosimilar Cell Line Development Service
  • Table 18.8 Cell Line Development Service Providers: Distribution by Availability of Gene Editing Cell Line Development Service
  • Table 18.9 Cell Line Development Service Providers: Distribution by Gene Delivery Methods Used
  • Table 18.10 Cell Line Development Service Providers: Distribution by Type of Gene Expression
  • Table 18.11 Cell Line Development Service Providers: Distribution by Availability of Serum-Free / Animal Component Free Culturing Capability
  • Table 18.12 Cell Line Development Service Providers: Distribution by Types of Cell Cultures
  • Table 18.13 Cell Line Development Service Providers: Distribution by Types of Cells Offered
  • Table 18.14 Cell Line Development Service Providers: Distribution by Applications of Cell Lines
  • Table 18.15 Cell Line Development Services Providers: Distribution by Types of Additional Cell Line Related Services Offered
  • Table 18.16 Cell Line Development Services Providers: Distribution by Type of Cell Bank(s) Developed
  • Table 18.17 Thermo Fisher Scientific: Annual Revenues, FY2015-H1 2020 (USD Billion)
  • Table 18.18 Lonza: Annual Revenues, FY 2015-H1 2020 (CHF Billion)
  • Table 18.19 WuXi Biologics: Annual Revenues, FY 2016-H1 2020 (RMB Billion)
  • Table 18.20 Cell Line Characterization Service Providers: Overall Market Landscape
  • Table 18.21 Cell Line Characterization Service Providers (Industry Players): Distribution by Year of Establishment
  • Table 18.22 Cell Line Characterization Service Providers (Industry Players): Distribution by Company Size
  • Table 18.23 Cell Line Characterization Service Providers (Industry Players): Distribution by Location of Headquarters
  • Table 18.24 Cell Line Characterization Service Providers: Distribution by Geography
  • Table 18.25 Cell Line Characterization Service Providers (Industry Players): Distribution by Types of Cells Handled
  • Table 18.26 Cell Line Development Service Providers (Industry Players): Analysis by Type of Cell Line Characterization Service(s) Offered
  • Table 18.27 Cell Line Characterization Service Providers (Industry Players): Type of Cell Line Identity / Stability Testing Service(s) Offered
  • Table 18.28 Cell Line Characterization Service Providers (Industry Players): Type of Cell Line Sterility / Biosafety Testing Service(s) Offered
  • Table 18.29 Cell Line Characterization Service Providers (Industry Players): Distribution by Availability of Additional Cell Line Related Services
  • Table 18.30 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Location of Organization
  • Table 18.31 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Types of Cells Handled
  • Table 18.32 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Type of Cell Line Characterization Service(s) Offered
  • Table 18.33 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Type of Genotyping Kit Used
  • Table 18.34 Cell Line Characterization Service Providers (Non-Industry Players): Distribution by Number of STR Loci Amplified
  • Table 18.35 Charles River Laboratories: Annual Revenues, 2015-Q3 2020 (USD Billion)
  • Table 18.36 Sartorius Stedim Biotech: Annual Revenues, 2015-Q3 2020 (EUR Billion)
  • Table 18.37 SGS: Annual Revenues, 2015-H1 2020 (CHF Billion)
  • Table 18.38 Partnerships and Collaborations: Cumulative Trend by Year of Partnership, 2015-2020
  • Table 18.39 Partnerships and Collaborations: Distribution by Type of Partnership
  • Table 18.40 Partnerships and Collaborations: Distribution by Year and Type of Partnership (2015-2020)
  • Table 18.41 Partnerships and Collaborations: Distribution by Type of Product being Licensed
  • Table 18.42 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
  • Table 18.43 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
  • Table 18.44 Most Active Players: Distribution by Number of Partnerships
  • Table 18.45 Partnerships and Collaborations: Regional Distribution
  • Table 18.46 Partnerships and Collaborations: Intercontinental and Intracontinental Distribution
  • Table 18.47 Most Popular Technology Platforms: Distribution by Number of Partnerships
  • Table 18.48 Partnerships and Collaborations: Distribution by Types of Cells Involved
  • Table 18.49 Partnerships and Collaborations: Distribution by Type of Target Disease Indication
  • Table 18.50 Global Cell Line Development Services Market: 2020-2030, Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.51 Global Cell Line Development Services Market: Distribution by Sources of Cell Lines, 2020 and 2030: Base Scenario (USD Million)
  • Table 18.52 Cell Line Development Services Market for Mammalian Cell Lines, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.53 Cell Line Development Services Market for Microbial Cell Lines, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.54 Cell Line Development Services Market for Insect Cell Lines, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.55 Cell Line Development Services Market for Avian Cell Lines, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.56 Global Cell Line Development Services Market: Distribution by Applications of Cell Lines, 2020 and 2030: Base Scenario (USD Million)
  • Table 18.57 Cell Line Development Services Market for Bioproduction, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.58 Cell Line Development Services Market for Research and Development Operations, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.59 Global Cell Line Development Services Market: Distribution by Company Size, 2020 and 2030: Base Scenario (USD Million)
  • Table 18.60 Cell Line Development Services Market for Small-sized Companies, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.61 Cell Line Development Services Market for Mid-sized Companies, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.62 Cell Line Development Services Market for Large Companies, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.63 Global Cell Line Development Services Market: Distribution by Geography, 2020 and 2030: Base Scenario (USD Million)
  • Table 18.64 Cell Line Development Services Market in North America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.65 Cell Line Development Services Market in Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.66 Cell Line Development Services Market in Asia, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.67 Cell Line Development Services Market in Oceania, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.68 Cell Line Development Services Market in the Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.69 Global Cell Line Characterization Services Market, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.70 Global Cell Line Characterization Services Market: Distribution by Types of Projects, 2020-2030: Base Scenario (USD Million)
  • Table 18.71 Global Cell Line Characterization Services Market: Distribution by Sources of Cell Lines, 2020 and 2030: Base Scenario (USD Million)
  • Table 18.72 Cell Line Characterization Services Market for Mammalian Cell Lines, 2020-2030: Base and Optimistic Scenarios (USD Million)
  • Table 18.73 Cell Line Characterization Services Market for Microbial Cell Lines, 2020-2030: Base and Optimistic Scenarios (USD Million)
  • Table 18.74 Cell Line Characterization Services Market for Other Cell Lines, 2020-2030: Base and Optimistic Scenarios (USD Million)
  • Table 18.75 Global Cell Line Characterization Services Market: Distribution by Applications of Cell Lines, 2020 and 2030: Base Scenario (USD Million)
  • Table 18.76 Cell Line Characterization Services Market for Bioproduction, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.77 Cell Line Characterization Services Market for Research and Development Operations, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.78 Global Cell Line Characterization Services Market: Distribution by Type of Service Provider, 2020 and 2030: Base Scenario (USD Million)
  • Table 18.79 Cell Line Characterization Services Market for Industry Players, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.80 Cell Line Characterization Services Market for Non-Industry Players, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.81 Global Cell Line Characterization Services Market: Distribution by Geography, 2020 and 2030: Base Scenario (USD Million)
  • Table 18.82 Cell Line Characterization Services Market in the US, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.83 Cell Line Characterization Services Market in Canada, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.84 Cell Line Characterization Services Market in the UK, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.85 Cell Line Characterization Services Market in France, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.86 Cell Line Characterization Services Market in the Germany, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.87 Cell Line Characterization Services Market in Spain, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.88 Cell Line Characterization Services Market in Italy, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.89 Cell Line Characterization Services Market in Rest of Europe, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.90 Cell Line Characterization Services Market in China, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.91 Cell Line Characterization Services Market in Japan, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.92 Cell Line Characterization Services Market in India, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.93 Cell Line Characterization Services Market in Latin America, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.94 Cell Line Characterization Services Market in Middle East and North Africa, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.95 Cell Line Characterization Services Market in the Rest of the World, 2020-2030: Conservative, Base and Optimistic Scenarios (USD Million)
  • Table 18.96 Survey Analysis: Distribution by Location of Organization
  • Table 18.97 Survey Analysis: Distribution by Location of Manufacturing Facilities
  • Table 18.98 Survey Analysis: Distribution by Seniority Level of Respondents
  • Table 18.99 Survey Analysis: Distribution by Type of Cell Lines
  • Table 18.100 Survey Analysis: Distribution by Source of Cell Lines
  • Table 18.101 Survey Analysis: Distribution by Applications of Cell Lines
  • Table 18.102 Survey Analysis: Cell Line Characterization Services
  • Table 18.103 Survey Analysis: Cell Banking Services
  • Table 18.104 Survey Analysis: Biologics Manufacturing Services
  • Table 18.105 Survey Analysis: Fill / Finish Services

List Of Companies

  • 1. 10x Genomics
  • 2. 3P Biopharmaceuticals
  • 3. 3SBio
  • 4. A&G Pharmaceutical
  • 5. Aarhus University Hospital
  • 6. AbbVie
  • 7. Abcam
  • 8. ABclonal
  • 9. Abcuro
  • 10. Abdi Ibrahim Pharmaceuticals
  • 11. Abeomics
  • 12. ABGENEX
  • 13. ABL Bio
  • 14. Abnova
  • 15. AbSci
  • 16. Abzena
  • 17. AC Immune
  • 18. AcceGen
  • 19. Accelero Bioanalytics
  • 20. Accuprec Research Labs
  • 21. Accuratus Lab Services
  • 22. Accurus Biosciences
  • 23. ACE Biolabs
  • 24. ACROBiosystems
  • 25. Acticor Biotech
  • 26. ACYTE Biotech
  • 27. Adagene
  • 28. AdaptVac
  • 29. AddexBio Technologies
  • 30. Advanced Biomart
  • 31. Advaxis
  • 32. Affinita Biotech
  • 33. A-Frontier
  • 34. AGC Biologics
  • 35. Agenus
  • 36. Airway Therapeutics
  • 37. Akers Biosciences
  • 38. Akshaya Bio
  • 39. Albany Molecular Research (AMRI)
  • 40. Albert Ludwigs University of Freiburg
  • 41. Aldevron
  • 42. Alligator Bioscience
  • 43. Almirall
  • 44. Alpha Lifetech
  • 45. ALSTEM
  • 46. Altogen Labs
  • 47. Alvotech
  • 48. America Pharma Source
  • 49. Amicus Therapeutics
  • 50. Ampersand Capital Partners
  • 51. AMS Biotechnology (AMSBIO)
  • 52. Analytical Biological Services (ABS)
  • 53. Analytical Lab Group
  • 54. Applied Biological Materials (abm)
  • 55. Applied Genetics Laboratories (AGL)
  • 56. APRINOIA Therapeutics
  • 57. Aragen Bioscience
  • 58. Aravive
  • 59. ARETA International (ARETAINT)
  • 60. Artelo Biosciences
  • 61. ARTES Biotechnology
  • 62. AscentGene
  • 63. ASLAN Pharmaceuticals
  • 64. Astellas Pharma
  • 65. Asymchem
  • 66. AtaGenix Laboratories
  • 67. American Type Culture Collection (ATCC)
  • 68. ATGCell
  • 69. ATUM (formerly DNA2.0)
  • 70. ATZ Labs
  • 71. Augusta University
  • 72. Australian Genome Research Facility (AGRF)
  • 73. Austrianova
  • 74. AutekBio
  • 75. Avacta
  • 76. Avance Biosciences
  • 77. Avaxia Biologics
  • 78. Avid Bioservices (formerly Peregrine Pharmaceuticals)
  • 79. Axol Bioscience
  • 80. Axon Scientific
  • 81. Baliopharm
  • 82. BaseClear
  • 83. Batavia Biosciences
  • 84. Bavarian Nordic
  • 85. Bayer
  • 86. Beckman Coulter
  • 87. Beckman Research Institute of City of Hope
  • 88. BeiGene
  • 89. Berkeley Lights
  • 90. Bex CO
  • 91. Bhat Bio-tech India
  • 92. BIBITEC
  • 93. Bio Farma
  • 94. Bioasis Technologies
  • 95. BioAzure Technologies
  • 96. Bioceros
  • 97. BIO-ENGINEERING
  • 98. BioFactura
  • 99. Bioingenium
  • 100. Biointron Biological
  • 101. BioInvenu
  • 102. BioLife Solutions
  • 103. Biologics International
  • 104. BioMax Lab
  • 105. Bionique Testing Laboratories
  • 106. Bionova Scientific
  • 107. BioPharmaceuticals Australia (BPA)
  • 108. BioReliance
  • 109. Biosettia
  • 110. Biosphere
  • 111. BioSun Pharmed
  • 112. Bio-Synthesis (BSI)
  • 113. Biotechnology Hub Africa
  • 114. BioTek Instruments
  • 115. BioTickle
  • 116. Biovian
  • 117. BJ Bioscience
  • 118. BLIRT (Biolab Innovative Research Technologies)
  • 119. BMR Genomics
  • 120. Boehringer Ingelheim Animal Health
  • 121. Boehringer Ingelheim BioXcellence
  • 122. Boston Institute of Biotechnology
  • 123. Boston Mountain Biotech
  • 124. BPS Bioscience
  • 125. BriaCell Therapeutics
  • 126. Brii Biosciences
  • 127. Bristol Myers Squibb
  • 128. Broad Institute of MIT and Harvard
  • 129. Brooks Automation
  • 130. Bruker
  • 131. Burnet Institute
  • 132. C&M Biolabs
  • 133. CALIXAR
  • 134. CANbridge Pharmaceuticals
  • 135. Canopy Biosciences
  • 136. Capital Biosciences
  • 137. Catalent Pharma Solutions
  • 138. Cell and Genome Engineering Core, University of California
  • 139. Cell Culture
  • 140. Cell Guidance Systems
  • 141. Cell Line Genetics
  • 142. Cellaria
  • 143. Cellca
  • 144. Cellero
  • 145. CellGenix
  • 146. CellKraft Biotech
  • 147. Cellomics Technology
  • 148. CellSafe
  • 149. Cells Online
  • 150. Celltheon
  • 151. Cellutron Life Technologies
  • 152. CELONIC Group (formerly Glycotope Biotechnology)
  • 153. Celplor
  • 154. Celther Polska
  • 155. Centre for Process Innovation (CPI)
  • 156. Cerbios-Pharma
  • 157. Ceva Santé Animale
  • 158. CEVEC Pharmaceuticals
  • 159. Changchun High & New Technology Industries Group
  • 160. Charles River Laboratories
  • 161. Children's Medical Research Institute
  • 162. ChinaPeptides
  • 163. Chiome Bioscience
  • 164. ChristianaCare's Helen F. Graham Cancer Center & Research Institute
  • 165. Cipla Gulf
  • 166. Clean Cells
  • 167. Cleveland Clinic Lerner Research Institute
  • 168. Clongen Laboratories
  • 169. CLS Cell Lines Service
  • 170. CMAB Biopharma
  • 171. CMIC
  • 172. Cobra Biologics
  • 173. COBRE Grant Genomics, Biostatistics and Bioinformatics Core, Tulane University
  • 174. Codex DNA (formerly SGI-DNA)
  • 175. Cognate BioServices
  • 176. Complix
  • 177. Compugen
  • 178. CORE Diagnostics
  • 179. Cosmo Bio
  • 180. Cosmogenetech
  • 181. Covance
  • 182. CPE
  • 183. Creative Bioarray
  • 184. Creative Biogene
  • 185. Creative Biolabs
  • 186. Creative BioMart
  • 187. CSL
  • 188. Curaxys
  • 189. Cytovance Biologics
  • 190. Cytiva
  • 191. CZ Veterinaria
  • 192. DC Biosciences
  • 193. DC3 Therapeutics
  • 194. DefiniGEN
  • 195. Delphi Genetics
  • 196. Denali Therapeutics
  • 197. Detai Bio-Tech
  • 198. Diagnostic Cytogenetics (DCI)
  • 199. DiethelmKellerSiberHegner (DKSH)
  • 200. DNA Diagnostics Center
  • 201. DNA Forensics Laboratory
  • 202. DPx Holdings
  • 203. Dr. KPC Life Sciences (formerly Chemgen Pharma)
  • 204. Duke University School of Medicine
  • 205. DYNAMIMED
  • 206. Early Drug Development Group (E2DG)
  • 207. Editas Medicine
  • 208. EirGenix
  • 209. Elabscience
  • 210. Element Materials Technology
  • 211. EMD Serono
  • 212. EMP Genetech
  • 213. Encure Biopharma
  • 214. EPICS Therapeutics
  • 215. EpiGex
  • 216. ERS Genomics
  • 217. Essen BioScience
  • 218. Eton Bioscience
  • 219. EuBiologics
  • 220. EUGENEX Biotechnologies
  • 221. EUPROTEIN
  • 222. Eurofins BioPharma Product Testing
  • 223. Eurofins DiscoverX
  • 224. Eurofins Discovery
  • 225. Eurofins Genomics
  • 226. Eurofins Scientific
  • 227. Eurogentec
  • 228. EuroscreenFAST
  • 229. Eutilex
  • 230. Evotec
  • 231. Evox Therapeutics
  • 232. Excelimmune
  • 233. ExcellGene
  • 234. exonbio
  • 235. ExpreS2ion Biotechnologies
  • 236. ExpressCells
  • 237. Extherid Biosciences
  • 238. Fapon Biotech
  • 239. Faron Pharmaceuticals
  • 240. Feinberg School of Medicine, Northwestern University
  • 241. First BASE Laboratories
  • 242. FlashCell
  • 243. FlowMetric Life Sciences
  • 244. Fountain Biopharma
  • 245. Fraunhofer Institute for Interfacial Engineering and Biotechnology IGB
  • 246. Fred Hutchinson Cancer Research Center
  • 247. French National Agency for Research on AIDS and Viral Hepatitis (ANRS)
  • 248. Fuji Pharma
  • 249. FUJIFILM Diosynth Biotechnologies
  • 250. Fusion Antibodies
  • 251. G&P Biosciences
  • 252. G&W Biotechnologie
  • 253. Gemini Biosciences
  • 254. Gene Center at Ludwig-Maximilians-Universität München
  • 255. Genea Biocells
  • 256. GeneBeyond
  • 257. GeneCopoeia
  • 258. Genedata
  • 259. Genenmed (formerly Cancercide)
  • 260. GENERI BIOTECH
  • 261. Generium
  • 262. Genetica DNA Laboratories
  • 263. GENEWIZ
  • 264. Genexplore Diagnostics and Research Centre
  • 265. GenomeScan
  • 266. Genovis
  • 267. genOway
  • 268. GenScript
  • 269. GenScript ProBio
  • 270. GenTarget
  • 271. GeoVax Labs
  • 272. German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ)
  • 273. German Collection of Microorganisms and Cell Cultures
  • 274. GHO Capital Partners
  • 275. GI Innovation
  • 276. GlaxoSmithKline
  • 277. GlycoBac
  • 278. Glycotope
  • 279. Goodwin Biotechnology
  • 280. Pfizer- University of Granada- Junta de Andalucía Centre for Genomics and
  • 281. Oncological Research (GENYO)
  • 282. Grid Therapeutics
  • 283. Griffith University
  • 284. GT Biopharma
  • 285. GTP Technology
  • 286. GVK Biosciences (GVK BIO)
  • 287. handyem
  • 288. Haplogen Genomics
  • 289. Harbour BioMed
  • 290. Harvest Moon Pharmaceuticals
  • 291. Heidelberg Pharma
  • 292. Helsinki Institute of Life Science (HiLIFE)
  • 293. HemaCare
  • 294. Hepalink USA
  • 295. Hera BioLabs
  • 296. HistoCyte Laboratories
  • 297. Hoba Therapeutics
  • 298. Horizon Discovery
  • 299. Humanigen
  • 300. hylabs (Hy Laboratories)
  • 301. Hyprocell
  • 302. IBI - Istituto Biochimico Italiano Giovanni Lorenzini
  • 303. IDEXX Laboratories
  • 304. I-Mab Biopharma
  • 305. ImmuneOncia Therapeutics
  • 306. ImmuNext
  • 307. ImmunoGenesis
  • 308. ImmunoPrecise Antibodies
  • 309. IMMUNOSTEP
  • 310. Inhibrx
  • 311. InSCREENeX
  • 312. Institut für Forensische Genetik (IFG)
  • 313. Integrated BioTherapeutics
  • 314. IntelliCyt
  • 315. International AIDS Vaccine Initiative (IAVI)
  • 316. Intervacc
  • 317. InVivo BioTech Services
  • 318. IRCCS San Martino Hospital - IST National Cancer Research Institute
  • 319. JAMP Pharma
  • 320. Janssen Biotech
  • 321. The Jenner Institute, University of Oxford
  • 322. JHL Biotech
  • 323. Johns Hopkins University
  • 324. JSR Life Sciences
  • 325. Shanghai Junshi Biosciences
  • 326. Just Biotherapeutics
  • 327. KBIO Health (Osong Advanced Medical Industry Promotion Foundation)
  • 328. KaryoLogic
  • 329. KBI Biopharma
  • 330. KEMP PROTEINS (formerly Kempbio)
  • 331. KMD Bioscience
  • 332. Korean Cell Line Bank
  • 333. Krishgen Biosystems
  • 334. KWR Water Research Institute
  • 335. KYinno
  • 336. Laboratorios Liomont
  • 337. Laboratory Corporation of America Holdings (LabCorp)
  • 338. LakePharma
  • 339. Laragen
  • 340. Laureate Biopharmaceutical Services
  • 341. Lava Therapeutics
  • 342. Legend Biotech
  • 343. Leiden University Medical Centre (LUMC)
  • 344. LFB Biomanufacturing
  • 345. Life Technologies (India)
  • 346. Limin International Group
  • 347. Lipum
  • 348. Livogen Pharmed
  • 349. Lonza
  • 350. Luminex
  • 351. Lumosa Therapeutics
  • 352. Mabion
  • 353. MabPlex International
  • 354. Mammoth Biosciences
  • 355. MassBiologics
  • 356. MaSTherCell Global
  • 357. University of Texas MD Anderson Cancer Center
  • 358. Medvet Science
  • 359. MeiraGTx
  • 360. Memo Therapeutics
  • 361. Memorial Sloan Kettering Cancer Center (MSK)
  • 362. Merck
  • 363. Merus
  • 364. MGC Pharma (subsidiary of Mitsubishi Gas Chemical)
  • 365. Michigan State University
  • 366. Microbiology & Quality Associates
  • 367. Microbiology Research Associates
  • 368. Microsynth
  • 369. Midas Pharma
  • 370. MilliporeSigma (formerly Sigma-Aldrich)
  • 371. Minapharm Pharmaceuticals
  • 372. Minerva Analytix
  • 373. Mithra Biotechnology
  • 374. MKS Instruments
  • 375. ModiQuest Research (acquired by ImmunoPrecise)
  • 376. Molecular Cloning Laboratories (MCLAB)
  • 377. Molecular Diagnostic Services
  • 378. Molecular Medicine (MolMed)
  • 379. Momenta Pharmaceuticals
  • 380. Moredun Scientific
  • 381. Mount Sinai Health System
  • 382. Multiplexion
  • 383. Multispan
  • 384. Mycenax Biotech
  • 385. Mycoplasma Experience
  • 386. Nashville Biosciences
  • 387. National Biologics Facility
  • 388. National Institute for Bioprocessing Research and Training (NIBRT)
  • 389. Naturalis Biodiversity Center
  • 390. Navrogen
  • 391. NewLink Genetics
  • 392. NGM Biopharmaceuticals
  • 393. Noachis Terra
  • 394. NorClone Biotech Laboratories
  • 395. Nordmark Biotech
  • 396. NorthGene
  • 397. Northway Biotechpharma
  • 398. Nouscom
  • 399. Novasep
  • 400. Novatein Biosciences
  • 401. Nucleome Informatics
  • 402. Oak BioSciences
  • 403. Octapharma
  • 404. Ogeda (formerly Euroscreen)
  • 405. Okmed Biotech
  • 406. Ology Bioservices (formerly Nanotherapeutics)
  • 407. Oncologie
  • 408. Oncotest
  • 409. OneWorld Biotech
  • 410. Oregon Health & Science University
  • 411. OSE Immunotherapeutics
  • 412. Oxford BioTherapeutics
  • 413. Oxford Expression Technologies (OET)
  • 414. Oxford Genetics (OXGENE)
  • 415. Oxford Nanopore Technologies (ONT)
  • 416. PacificGMP
  • 417. Pall Biotech
  • 418. PanGen Biotech
  • 419. Paragon Bioservices
  • 420. Paraza Pharma
  • 421. PATH
  • 422. Patheon
  • 423. PathoQuest
  • 424. Pelican Therapeutics
  • 425. Penn Purchasing Services, University of Pennsylvania
  • 426. Perfectus Biomed (formerly Extherid Biosciences)
  • 427. Phanes Therapeutics
  • 428. PharmAbcine
  • 429. Pharmaron
  • 430. PhaseBio Pharmaceuticals
  • 431. Phylex BioSciences
  • 432. Pieris Pharmaceuticals
  • 433. Pionyr Immunotherapeutics (formerly Precision Immune)
  • 434. Polpharma Biologics
  • 435. Polymun Scientific
  • 436. Porton Biologics
  • 437. Precision Antibody
  • 438. Premas Biotech
  • 439. Prestige Biopharma
  • 440. Probiodrug
  • 441. ProBioGen
  • 442. Profacgen
  • 443. Progenics Pharmaceuticals
  • 444. Promega
  • 445. PROMISE Proteomics
  • 446. Protein Technologies
  • 447. ProteinCT Biotech
  • 448. ProteoCell Biotechnologies
  • 449. ProteoGenix
  • 450. ProteoNic
  • 451. PX'Therapeutics (formerly Protein'eXpert)
  • 452. QED Bioscience
  • 453. qGenomics
  • 454. QIMR Berghofer Medical Research Institute
  • 455. QuaCell Biotechnology
  • 456. Queen's University Belfast
  • 457. Rajiv Gandhi Centre for Biotechnology
  • 458. RD-Biotech
  • 459. ReliaTech (Receptor Ligand Technologies)
  • 460. Relief Therapeutics
  • 461. Rentschler Biopharma
  • 462. Richter-Helm BioLogics
  • 463. Roche
  • 464. Rockland Immunochemicals
  • 465. Rodon Biologics
  • 466. Roswell Park Comprehensive Cancer Center
  • 467. Rubicon Genomics
  • 468. SAL Scientific
  • 469. Samsung Biologics
  • 470. Sandoz
  • 471. Sanford Burnham Prebys Medical Discovery Institute
  • 472. Sanofi
  • 473. Sanyou Biopharmaceuticals
  • 474. Sartorius Stedim BioOutsource
  • 475. Sartorius Stedim Biotech
  • 476. Sartorius Stedim Cellca
  • 477. SB Drug Discovery
  • 478. SecuGen
  • 479. Selecxine
  • 480. Selexis
  • 481. Serum Institute of India
  • 482. SGS
  • 483. Shanghai Biowing Applied Biotechnology
  • 484. Shanghai ChemPartner
  • 485. Shanghai Medicilon
  • 486. Shanghai Optima Biotechnology
  • 487. Molecular Diagnostics Laboratory of Dana - Farber Cancer Institute
  • 488. Shenzhen Hepalink Pharmaceutical
  • 489. Shire
  • 490. Sigma-Aldrich
  • 491. Signosis
  • 492. Sinensis Life Sciences
  • 493. Sino Biological
  • 494. Six.02 Bioservices
  • 495. Solentim
  • 496. Sparta Systems
  • 497. SPEED Biosystems
  • 498. Sphere Fluidics
  • 499. Spicona
  • 500. STADA Arzneimittel
  • 501. Statens Serum Institut
  • 502. STC Biologics
  • 503. STCube
  • 504. Summit Pharmaceuticals International (SPI)
  • 505. Sundia MediTech
  • 506. Sunomix Biosciences
  • 507. Surface Oncology
  • 508. Svar Life Science (formerly Euro Diagnostica)
  • 509. Swedish Orphan Biovitrum
  • 510. SwissLumix
  • 511. Syd Labs
  • 512. Syngene International
  • 513. Synovel Sciences
  • 514. Synpromics
  • 515. System Biosciences
  • 516. Takeda Pharmaceutical
  • 517. TCG Lifesciences
  • 518. tebu-bio
  • 519. Technion Israel Institute of Technology
  • 520. Teneobio
  • 521. TentaMedix (formerly MicroMol)
  • 522. Teva Pharmaceutical
  • 523. Texcell
  • 524. TFBS Bioscience
  • 525. The Beatson Institute for Cancer Research, University of Glasgow
  • 526. The Centre for Applied Genomics (TCAG)
  • 527. The European Collection of Authenticated Cell Cultures (ECACC)
  • 528. The Garvan Institute of Medical Research
  • 529. The Helmholtz Protein Sample Production Facility (PSPF)
  • 530. The Hospital for Sick Children (SickKids)
  • 531. The Human Protein Atlas
  • 532. The Microbial Type Culture Collection and Gene Bank (MTCC)
  • 533. The Native Antigen Company
  • 534. The Pirbright Institute
  • 535. The State University of New York at Albany
  • 536. The University of Manchester
  • 537. The University of Sheffield
  • 538. The University of Texas Medical Branch (UTMB)
  • 539. The University of Vermont (UVM)
  • 540. The Westmead Institute for Medical Research
  • 541. The Wistar Institute
  • 542. Therachon
  • 543. Therapure Biopharma
  • 544. Thermo Fisher Scientific
  • 545. Tizona Therapeutics
  • 546. Toleranzia
  • 547. TPG Biologics
  • 548. Translational Research Platform for Veterinary Biologicals (TRPVB)
  • 549. Transposagen Biopharmaceuticals
  • 550. TransViragen
  • 551. Trend Pharma & Tech
  • 552. Trenzyme
  • 553. TrueBinding (formerly Immutics)
  • 554. Turgut Pharmaceuticals
  • 555. TWIN HELIX
  • 556. Twist Bioscience
  • 557. Twist Bioscience
  • 558. Ubiquigent
  • 559. UC Berkeley DNA Sequencing Facility, University of California
  • 560. UGA Biopharma
  • 561. UNC School of Medicine
  • 562. United BioLabs
  • 563. United Biomedical (UBI)
  • 564. United BioPharma (UBP)
  • 565. University of Arizona
  • 566. University of Cambridge
  • 567. University of Colorado Anschutz Medical Campus
  • 568. University of Connecticut
  • 569. University of Edinburgh
  • 570. University of Florida
  • 571. University of Illinois
  • 572. University of Maryland
  • 573. University of Missouri
  • 574. University of Pennsylvania
  • 575. University of Pittsburgh
  • 576. University of Sussex
  • 577. University of Technology, Sydney
  • 578. University of Utah
  • 579. University of Warsaw
  • 580. University of Wisconsin School of Medicine and Public Health
  • 581. U-Protein Express
  • 582. UT Southwestern Medical Center
  • 583. Vaccine Research Institute (VRI)
  • 584. Vaccinex
  • 585. Vaccitech
  • 586. Valerius Biopharma
  • 587. Vall d'Hebron Research Institute
  • 588. Vectalys
  • 589. VectorBuilder
  • 590. Vectron Biosolutions
  • 591. VelaLabs
  • 592. Veterinary Medical Research & Development (VMRD)
  • 593. Vibalogics
  • 594. Vir Biotechnology
  • 595. Virongy
  • 596. ViruSure
  • 597. Vista Biologicals
  • 598. VTU Technology
  • 599. VxP Biologics
  • 600. Waisman Biomanufacturing
  • 601. Washington University in St. Louis
  • 602. WatsonBio Sciences
  • 603. Wayne State University
  • 604. Welgen
  • 605. Wuhan Dian Biotechnology
  • 606. WuXi Advanced Therapies
  • 607. WuXi AppTec
  • 608. WuXi Biologics
  • 609. Wyndham Forensic Group
  • 610. Xell
  • 611. Xencor
  • 612. Yale University
  • 613. Zellkraftwerk
  • 614. Zhejiang University
  • 615. Zumutor Biologics
  • 616. Zymeworks
  • 617. ZyVersa Therapeutics